and challenges for future research. J Bone Miner Res 2011;26:2317–2337.
26Cheng Z, Zou S, Peng D, Zhang G, Zhu X: Prognostic value of 99mTc-sestamibi parathyroid scintigraphy in predicting future surgical eligibility in patients with asymptomatic primary hyperparathyroidism. Clin Nucl Med 2018;43:151–154.
27Sun B, Guo B, Wu B, Kang J, Deng X, Zhang Z, Fan Y: Characteristics, management, and outcome of primary hyperparathyroidism at a single clinical center from 2005 to 2016. Osteoporos Int 2018;29:635–642.
28Stephen AE, Mannstadt M, Hodin RA: Indications for surgical management of hyperparathyroidism: a review. JAMA Surg 2017;152:878–882.
29Consensus Development Conference Panel: Diagnosis and management of asymptomatic primary hyperparathyroidism: Consensus Development Conference Statement. Ann Intern Med 1991;114:593–597.
30Bilezikian JP, Potts JT Jr, Fuleihan Gel-H, et al: Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab 2002;87:5353–5361.
31Bilezikian JP, Khan AA, Potts JT Jr; Third International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism: Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Third International Workshop. J Clin Endocrinol Metab 2009;94:335–339.
32Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, Potts JT Jr: Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 2014;99:3561–3569.
33Rubin MR, Bilezikian JP, McMahon DJ, et al: The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 2008;93:3462–3470.
34Polistena A, Lucchini R, Monacelli M, Triola R, Avenia S, Barillaro I, Johnson LB, Sanguinetti A, Avenia N: Current indications for surgical treatment of primary hyperparathyroidism in the elderly. Am Surg 2017;83:296–302.
35Quak E, Blanchard D, Houdu B, Le Roux Y, Ciappuccini R, Lireux B, de Raucourt D, Grellard JM, Licaj I, Bardet S, Reznik Y, Clarisse B, Aide N: F18-choline PET/CT guided surgery in primary hyperparathyroidism when ultrasound and MIBI SPECT/CT are negative or inconclusive: the APACH1 study. Eur J Nucl Med Mol Imaging 2018;45:658–666.
36Ajmi S, Sfar R, Trimeche S, Ben Ali K, Nouira M: Scintigraphic findings in hungry bone syndrome following parathyroidectomy. Rev Esp Med Nucl 2010;29:81–83.
37Wilhelm SM, Wang TS, Ruan DT, Lee JA, Asa SL, Duh QY, Doherty GM, Herrera MF, Pasieka JL, Perrier ND, Silverberg SJ, Solórzano CC, Sturgeon C, Tublin ME, Udelsman R, Carty SE: The American Association of Endocrine Surgeons guidelines for definitive management of primary hyperparathyroidism. JAMA Surg 2016;151:959–968.
38Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, Potts JT Jr: Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 2014;99:3561–3569.
39Orr-Walker BJ, Evans MC, Clearwater JM, Horne A, Grey AB, Reid IR: Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four-year follow-up and comparison with healthy postmenopausal women. Arch Intern Med 2000;160:2161–2166.
40Cesareo R, Di Stasio E, Vescini F, Campagna G, Cianni R, Pasqualini V, Romitelli F, Grimaldi F, Manfrini S, Palermo A: Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism. Osteoporos Int 2015;26:1295–1302.
41Rubin MR, Lee KH, McMahon DJ, Silverberg SJ: Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2003;88:1174–1178.
42Peacock M, Bolognese MA, Borofsky M, et al: Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. J Clin Endocrinol Metab 2009;94:4860–4867.
Bart L. Clarke, MD
Mayo Clinic E18-A
200 1st Street SW
Rochester, MN 55905 (USA)
E-Mail [email protected]
Brandi ML (ed): Parathyroid Disorders. Focusing on Unmet Needs.
Front Horm Res. Basel, Karger, 2019, vol 51, pp 23–39 (DOI: 10.1159/000491036)
______________________
Normocalcemic Hyperparathyroidism
Sabrina Corbetta
Endocrinology and Diabetology Service and Laboratory of Experimental Endocrinology, Department of Biomedical Sciences for Health, University of Milan, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy
______________________
Abstract
Parathyroid hormone (PTH) disorders are characterized by a wide spectrum of clinical and biochemical presentations. The increasing use of serum PTH assay in the set of the diagnostic workout in patients with osteoporosis has identified patients with features of surgically confirmed primary hyperparathyroidism (PHPT) associated with persistent normal serum calcium levels, which has been recognized as a distinct entity from hypercalcemic PHPT (HPHPT) by the last international consensus. Normocalcemic PHPT (NPHPT) affects about 6–8% of PHPT patients. Although hypercalcemia is absent, patients with NPHPT experience kidney, bone, and cardiovascular impairments similar to those observed in HPHPT, suggesting that NPHPT may significantly affect the health of patients. Diagnosis of NPHPT requires an intensive diagnostic workup aimed to: (1) exclude all causes of secondary hyperparathyroidism, and (2) evaluate the occurrence of PTH-related diseases. The management of NPHPT is controversial in part due to lack of solid data about the natural history as well as the effects of surgical or medical treatments. Nonetheless, a clinical and biochemical follow-up is recommended in order to detect potential progression. When hypercalcemia and/or PTH-related disorders arise, parathyroidectomy can be considered. When surgery is not advisable, medical treatment aimed to increase bone mineral density may be a therapeutic option.
